Peptides
HGH Fragment 176-191 (AOD-9604)
Also called AOD-9604 · HGH Frag · AOD9604 · Fragment 176-191
HGH fragment products are sought for fat loss without taking full growth hormone. The important catch is that sellers often blur HGH Fragment 176–191 and AOD-9604, while the larger human AOD-9604 obesity trial did not establish a weight-loss advantage over placebo.
Dosage & duration
One supplier’s published HGH Fragment 176–191 example; not a validated AOD-9604 regimen.
Fortex Pharma supplier example
Reported use · unapproved regimen- Dose
- 250–500 mcg per injection (0.25–0.5 mg)
- How often
- One or two times daily, under the skin
- How long
- 2–3 months in the supplier guide
These are supplier-described amounts and courses, not established safe or effective treatment. Product identity is not independently verified.
Sources: 2
Per-injection amount is different from the daily total. The supplier’s timing and duration do not demonstrate fat-loss benefit.
The practical difference
HGH fragment and AOD-9604: check the identity
The fat-loss claims often blur two different compounds.
| What differs | HGH Fragment 176–191 | AOD-9604 |
|---|---|---|
| Identity | Native HGH fragment name | Related modified compound |
| Human weight-loss evidence | A marketed vial cannot inherit AOD-9604 evidence | The larger oral trial found no significant advantage over placebo |
Why people try it
The appeal is a narrower fat-loss effect than full growth hormone. That does not establish spot reduction, muscle gain or the same effects as HGH. A marketed “fragment” vial cannot inherit all the evidence of a related research compound.
Check which compound is being discussed
Sellers often use these names interchangeably. Native HGH Fragment 176–191 and modified AOD-9604 should not be assumed identical. The human trial record most often cited belongs to AOD-9604.
What the trial result means for expectations
The larger oral AOD-9604 study did not show a significant weight-loss difference from placebo. Switching the discussion to injected fragment does not supply positive human proof. Reports about fasted cardio or timing are experiences, not established requirements.
Model details: HGH Fragment 176-191 (AOD-9604) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 12 hours
- Absorption half-life assumed
- 3 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Product identity, free-base/salt basis and route must be specified before absolute calibration. The stored 12-hour timing is unsupported, not a source-backed elimination half-life.
- FDA AOD-9604 briefing, December2024
Defines AOD-9604 as Tyr-hGH177–191; clinical PK section reports no identified human PK/PD studies. Nonclinical exposure findings cannot validate a generic human SC curve.
hgh-frag-176-191-relative-timing-2026-10 · version 1
Common questions
Is the fragment the same as full HGH?
No. A short fragment is not the full hormone and should not be expected to reproduce all its effects.
Are AOD-9604 and HGH Fragment 176–191 interchangeable?
Do not assume so. The names are mixed in marketing, but the sequence and studied formulation matter.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- A marketing goal, not a demonstrated substitute for growth hormone.
- Name confusion
- Confirm the sequence/formulation before comparing evidence.
- Expectation
- The larger related oral trial was negative.
- 1. FDA 2024 AOD-9604 scientific review
Human obesity evidence including the negative larger oral trial; not verification of marketed injectable fragment efficacy.
- 2. Fortex Pharma — HGH Fragment 176–191 product page
Original supplier page opened 7 Oct 2026. Declared 176–191 product; publishes 0.25–0.5 mg per SC injection, 1–2 times daily, 2–3 month courses. Evidence only of supplier-described use, not verified identity, human benefit or safety. Fasted/cardio efficacy, IGF-1 and broad safety claims not adopted.
- 3. FDA AOD-9604 briefing, December2024
Defines AOD-9604 as Tyr-hGH177–191; clinical PK section reports no identified human PK/PD studies. Nonclinical exposure findings cannot validate a generic human SC curve.
- 4. Metabolic Pharmaceuticals — 2007 trial announcement
Original sponsor filing cited by FDA: larger oral obesity trial did not meet weight-loss endpoints and program was terminated.
Related compounds and examples
Related compounds
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.
Semaglutide Oral (Rybelsus)
Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.
Tirzepatide (Mounjaro)
Tirzepatide can reduce appetite and food intake, helping people lose weight and improve blood-sugar control. In the US, Zepbound is the weight-management brand and Mounjaro treats type 2 diabetes. Both are weekly injections; digestive side effects and the right dose for the treatment goal are the main practical trade-offs.